小剂量沙利度胺联合MP方案治疗初治多发性骨髓瘤32例  

Low -dose thalidomide combined with MP in the treatment of 32 multiple myeloma cases

作　　者：王志芳[1] 刘非[1] 李金红[1] 孟祥玲[1] 赵恩锋[1] 

机构地区：[1]河北省沧州中西医结合医院血液内科,河北沧州061001

出　　处：《现代肿瘤医学》2013年第8期1850-1851,共2页Journal of Modern Oncology

摘　　要：目的:探讨沙利度胺联合MP方案治疗多发性骨髓瘤的疗效。方法:对应用沙利度胺联合MP治疗的32例患者的临床资料进行回顾性分析。结果:初治病例32例给予沙利度胺联合MP方案治疗,总有效率为81.2%。结论:沙利度胺联合MP方案治疗初治多发性骨髓瘤具有缓解率优于以往的常规MP方案治疗,且副作用少,耐受性好,疗效确切。Objective：To discuss the clinical efficacy of thalidomide combined with MP in patients with multiple myeloma.Methods：Clinical data of 32 patients with newly diagnosed multiple myelom treated by thalidomide combined with MP was analyzed retrospectively.Results：All 32 patients with newly diagnosed multiple myeloma were treated by thalidomide combined with MP,the total effective rate was 81.2%.Conclusion：Thalidomide combined with MP in the treatment of newly diagnosed multiple myelom is better than that of conventional therapy scheme（MP）,and with less side effects,good tolerance.

关 键 词：沙利度胺 多发性骨髓瘤 MP方案 

分 类 号：R733.3[医药卫生—肿瘤]